The evolving landscape of immunotherapy in small-cell lung cancer: a focus on predictive biomarkers

Small Cell Lung Cancer (SCLC) accounts for 15-17% of all lung cancers. Most patients have metastatic disease at the time of diagnosis, with a 5-year survival rate of only 2-8%. In this context, unfortunately, no improvement in survival has been achieved in the last 30 years [1]. In first-line setting, the standard of care is still based on platinum-etoposide [2], with platinum-irinotecan being an alternative option in Japan [3]. Although high response rates to first-line chemotherapy are observed (around 70-80%), most patients relapse within few months, leading to a median overall survival (mOS) of 8-12 months [4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Hot Topic Source Type: research